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1. Introduction  
1.1 Clinical implications 
End-stage liver disease is a life-threatening condition for which the only effective medical 
treatment available to date is orthotropic liver transplantation. Other approaches are needed 
because of the severe shortage of donors. These alternatives include cell transplantation and 
extracorporeal bioartificial livers. Since adult hepatocytes do not readily proliferate in 
culture, and healthy human livers are used to meet transplantation needs and are therefore 
not available for other purposes, a major challenge for these cell-based therapies is to 
identify a reliable hepatocyte source[1]. In the case of extracorporeal devices, many have 
suggested the use of animal sources (e.g. rat and pig), where immunoisolation may be 
possible. This is not likely to be a viable option for cell implantable modalities since these 
implants must be vascularized to function properly, and as a result would be exposed to 
xenogeneic immune rejection[2]. An increasingly plausible approach is the use of 
hepatocytes derived from embryonic stem cells (ESCs), as recent studies – reviewed in 
greater detail below – show that it is possible to differentiate ESCs into hepatocyte-like cells 
with high yields. Furthermore, recent developments with induced pluripotent stem cells 
(iPSCs) suggest that many of the procedures used to differentiate ESCs could be used on 
iPSCs, thus making it possible to derive patient-specific syngeneic hepatocytes. Besides 
therapeutic applications, hepatocytes derived from human ESCs can be used for a variety of 
other applications, such as toxicity drug screening, where the use of human cells is much 
preferred compared to animal cells that often vary in sensitivity and metabolism of 
xenobiotics and drugs. 
1.2 Industrial implications 
One of the fundamental challenges facing the development of new chemical entities within 
the pharmaceutical industry is the extrapolation of key in vivo parameters from in vitro cell 
culture assays and animal studies. Development of microscale devices and screening assays 
incorporating primary human cells can potentially provide better, faster and more efficient 
prediction of in vivo toxicity and clinical drug performance[3]. With this goal in mind, large 
strides have been made in the area of microfluidics to provide in vitro surrogates that are 
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designed to mimic the physiological architecture and dynamics. Current embodiments of 
this synergy cover various microelectromechanical (MEMs) devices that contain 
hepatocytes, for use in drug metabolism screening and toxicology assessment. 
1.3 Liver function and structure 
The liver, a key metabolic and detoxification center, contains parenchymal cells called 
hepatocytes (70%) and various nonparenchymal cell types such as sinusoidal endothelial 
cells, stellate (fat-storing, Ito) cells, Kupffer cells, and cholangiocytes (bile duct cells). 
Hepatocytes are responsible for most liver-specific functions, including albumin synthesis, 
detoxification of ammonia into urea and glutamine, bile and cholesterol production [4]. The 
liver is also critical for maintaining circulating glucose levels via gluconeogenesis during 
fasting. A large array of enzymes is responsible for the detoxification of organic compounds, 
either endogenous (such as many hormones) or exogenous (drugs and toxins) via two 
sequential mechanisms described as Phase I and Phase II biotransformations. There is an 
extensive body of literature that has shown that controlling environmental parameters, in 
other words the culture conditions, which consist of the type of substrate used, spatial 
orientation of the cultured cells, addition of growth factors, and the combinatorial effects of 
these parameters, is critically important to induce and maintain a high level of 
hepatocellular viability and function[5]. The functional and structural complexity of the 
liver organ has been very difficult to reproduce ex vivo in hepatocyte culture systems. Some 
of these challenges have been partially met using novel cell culture approaches as well as 
microfabrication techniques that can emulate the size scales of the liver sinusoid. While all 
of these studies describe various techniques to boost in vitro hepatocyte function, they do 
not resolve the limited access to primary hepatocytes, which do not proliferate to any 
significant degree outside of the liver[1]. This is crucial because despite modifications in the 
culture environment, large numbers of mature hepatocytes are needed, and yet, are not 
available, for clinical applicability. Herein, we focus primarily on the challenge of securing a 
sufficient supply of high functioning hepatocytes for clinical and industrial applications 
using a stem cell differentiation platform. 
1.4 Adult stem cells  
To address cell source issues more effectively, research into alternate hepatocyte precursor 
populations has been conducted. Unlike differentiated cells, hepatoblasts are not only 
capable of expressing differentiated function, but are also able to self-renew. A few 
hepatoblasts have been identified that have the capacity to differentiate into mature 
hepatocytes and include bipotential precursors for hepatocytes and biliary cells, and 
hematopoietic stem cells [6].  
In scenarios following severe hepatic injury, liver regeneration is attributed to a potential 
stem cell compartment located within the smallest branches of the intrahepatic biliary tree, 
which gives rise to the bipotential cells known as oval cells [7]; [8]. Oval cells are 
characterized as small cells with a high nucleus-to-cytoplasm ratio, oval shaped nucleus, 
and the ability to express markers of both fetal hepatocytes and biliary cells [9]; [10]. Oval 
cells have been shown to require growth factors such as transforming growth factor alpha 
(TGF, epidermal growth factor (EGF), and hepatocyte growth factor (HGF) for 
progression through the cell cycle as well and subsequent differentiation toward mature 
hepatocytes [11]. Despite the large number of observations describing liver growth 
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processes driven by oval cell proliferation and differentiation into hepatocytes, oval cells are 
difficult to isolate and the molecular mechanisms behind these processes must still be 
elucidated. 
Hematopoietic stem cells (HSCs) have also been induced to differentiate along hepatocyte 
specific pathways. For example, one experimental system utilized HSC transplantation to 
alleviate liver disease in fumarylacetoacetate hydrolase (FAH) deficient mice [12]. FAH 
deficiency leads to liver dysfunction and eventual lethality. Following HSC transplantation, 
liver function was reconstituted. However, it is unclear whether the HSCs or HSC progeny 
that repopulated the liver. In addition, the mechanism that induces differentiation toward 
mature hepatocytes is unclear. 
Despite the fact that hepatoblasts exhibit the potential to provide a renewable hepatocyte 
cell source, these cells are hard to isolate and exist in very low numbers [13]. In addition, the 
full efficacy of utilizing these precursor cells is questionable, since the long-term functional 
stability of hepatocytes obtained from these systems has yet to be assessed.  
2. Embryonic stem cells and induced pluripotent stem cells  
There are multiple stem cell starting paths for hepatocytes: 1. ESCs, 2. iPSCs, 3. Endoderm 
precursors and 4. Hepatic stem cells. However, due to their robust nature and large body of 
literature, we will focus on the first two. Furthermore these two cell types are readily 
abundant and have a higher proliferative capacity, thereby providing a strong potential 
starting point for the aforementioned applications. 
2.0.1 Embryonic stem cells (ES cells) 
Embryonic stem cells, derived from the inner cell mass of the blastocyst [14], have been 
proposed as another potential source for the generation of mature hepatocytes. ES cells are 
pluripotent and can be induced to differentiate into any cell type. When cultured in the 
presence of an anti-differentiation agent such as leukemia inhibitory factor (LIF) and with or 
without a feeder layer, these cells can proliferate while maintaining pluripotency [15]. Upon 
removal of the anti-differentiation agent, ES cells begin to spontaneously differentiate.  
2.0.2 Induced pluripotent stem cells (iPS cells) 
A new area of research has developed in recent years, majorly in part due to the legislative 
restrictions certain countries have placed on ES cell research. One area that has shown 
strong advancement is the area of induced pluripotent stem cells (iPS cells). iPS cells are the 
result of reprogramming somatic cells to a pluripotent state which resemble ES cells with 
respect to  morphology, proliferation (self- renewal), surface antigens, gene expression, 
epigenetic status of pluripotent cell-specific genes, epigenomics and telomerase activity [16, 
17]. Human iPS cells’ autologous nature offers several advantages over human ES cells in 
regards to potential patient specific therapeutics, the study of disease state, study of 
developmental processes, drug discovery as well as drug toxicity on differentiated 
hepatocytes while avoiding the ethical issues associated with isolation and the usage of 
human ES cells as illustrated in Figure 1.  
Yamanaka coined the term induced pluripotent stem cells in 2006 while inducing a 
pluripotent state in mouse somatic cells by direct reprogramming [16]. The same year, his 
lab demonstrated the generation of induced pluripotent stem cells from adult human  
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Fig. 1. Applications of IPS Cell Technology 
Patient-derived iPS cells can produce various somatic cells with the same genetic 
information as the patient. These cells could be used to construct disease models and to 
screen for effective and safe drugs, as well as to treat patients through cell transplantation 
therapy. (Figure taken from [20], figure 1) 
fibroblasts by retroviral transfection of four factors: Oct3/4, Sox2, c-Myc and Klf4 [16, 18]. 
Since then, others have generated human iPS cells using different combination of factors 
while preserving Oct3/4 and Sox2 as the core factors needed for pluripotency 
reprogramming while Oct3/4 is the most important[19, 20]. The main risk associated with 
the use of human iPS derived cells for transplantation is directly influenced by the iPS 
generation methods which may involve risk of DNA modification (gene deletion, viral gene 
incorporating into the human genome and gene expression alterations) which may lead to 
insertional mutations that will affect iPS function, differentiation potential and 
tumorigenesis [20, 21]. The human iPS cells generated by the Yamanaka group, for example, 
had more than 20 retroviral integration sites in total which may increase tumor formation 
[16, 18]. That risk has accelerated the search for new methods for generating clinically safer 
iPS cells such as the use of non-integrating episomal vectors or the use of molecules that 
promote or enhance reprogramming of somatic cells to iPS cells to improve reprogramming 
efficiency and reduce genomic alterations due to viral integration [21, 22].  
2.0.3 Induced pluripotent stem cells are similar, but not identical to embryonic stem 
cells 
Although iPS cells share similar features with ES cells as mentioned above, they are not 
identical. The reprogramming process does not involve genetic transformation but rather an 
epigenomic one. Lister et al. have shown that iPSCs are not identical to ESCs with respect to 
epigenomic profile by profiling whole-genome DNA methylation at single-base resolution 
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in five human iPSC lines, along with methylomes of ES cells, somatic cells, and 
differentiated iPSCs and ES cells [17]. In addition, iPSCs maintain some epigenomic features 
which resemble the somatic cell they have been generated from [17]. Cell memory based on 
epigenomics may suggest that, for example, iPSCs which were generated from primary 
hepatocytes as a somatic cell source will yield more or better functioning iPSC derived 
hepatocytes compared to those generated from iPSCs which were generated from fibroblasts 
as a somatic cell source. These discrepancies between human ES and iPS cells led to the 
question of what is the difference between the two stem cell types in regards to pluripotency 
and differentiation potential? And what is the best method to assess it? The ultimate test for 
pluripotency in the mouse system is the generation of a chimeric mouse which was 
successfully generated by blastocyst microinjection of mouse ES and iPS cells. Obviously, 
this test is not applicable to human ES and iPS cells and, therefore, other methods are being 
used to determine the pluripotency of the cells such as teratoma formation. As in the case of 
human ES cells, human iPS cells have the potential to differentiate to any of the three germ 
layers and form teratomas when transplanted subcutaneously into a severe combined 
immunodefficient (SCID) mouse [16, 18]. Unfortunately, teratoma formation does not 
guarantee full reprogramming as many mouse ES cell-like cell lines form teratomas but fail 
to produce germline chimeras [20]. The ultimate method to assess the differentiation 
potential of human ES and iPS cells to mature and functional hepatocytes is to compare the 
two with respect to mature hepatocytes gene and protein expression profiles, as well as 
metabolic activity, drug clearance, glycogen storage, urea and albumin synthesis and 
secretion while using the same differentiation method. 
In addition to the functionality of the differentiated hepatocytes, the efficiency of the process 
is of high importance due to the potential of human ESCs and iPSCs to differentiate 
spontaneously into cells from the three germ layers. Complete differentiation of stem cells in 
vitro is especially important when used for cell based therapies. Heterogeneous populations 
at the end of the differentiation process composed of differentiated cells as well as stem cells 
may lead to teratoma formation at the site of transplantation as well at other locations to 
which the cells migrated.  
2.1 Traditional embryonic stem cell and induced pluripotent stem cell differentiation 
paradigms 
Many paradigms currently exist to specifically direct the differentiation of embryonic 
stem cells toward a hepatocyte lineage in vitro, while utilizing the knowledge of 
embryological pathways occurring in vivo during normal liver development. This process 
involves numerous stages and is influenced by cytokines as well as cell-matrix 
interactions in a temporal and spatial manner. When developing new paradigms for 
direct differentiation of human ES and iPS cells into mature and functional hepatocytes in 
vitro with high efficiency, one must refer to the developmental process of the liver during 
embryonic development. 
2.1.1 Hepatocyte differentiation during embryogenesis 
The main stages are illustrated in Figure 2A. In the first phase, ES cells differentiate to 
endodermal cells. ES and iPS cells are pluripotent and therefore can give rise to any of the 
three germ layers: ectoderm, mesoderm and endoderm where the latter, more specifically 
the anterior- ventral definitive endoderm, give rise to the cells of the liver. The expression of 
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Wnt signaling inhibitors in the anterior endoderm represses the Wnt/ catenin pathway 
and was shown to be required for liver specification in the endoderm [23]. Signaling by the 
transforming growth factor beta (TGF┚) growth factor Nodal at relatively high 
concentrations initiates endoderm formation. Nodal signaling stimulates the expression of a 
core group of endoderm transcription factors including the HMG domain DNA-binding 
factor Sox17 and the fork head domain proteins Foxa1–3 (HNF3┙/┚/┛) which in turn 
regulate a cascade of genes committing cells to the endoderm lineage [24]. FoxA2 and 
GATA4 serve as transcription factors for the alb1 gene which encodes for serum albumin 
and appear early in the pre-liver hepatic domain of ventral foregut endoderm and later in 
liver [25, 26].     
 
  
                     (A)                                                                         (B) 
Fig. 2. Embryonic development of the liver. 
(A) Development of the liver is illustrated from the standpoint of cellular differentiation 
(red) from uncommitted endoderm to functional adult hepatocytes and biliary epithelium. 
(B) The schematic shows mouse embryos at different stages of development with the 
endoderm tissue highlighted in yellow, the liver in red, and the gall bladder in green. The 
major developmental events are listed below. The endoderm germ layer is formed during 
gastrulation (e6.5-e7.5). Throughout gastrulation and early somite stages of development 
(e7-e8.5) the endoderm is patterned along the A-P axis into foregut (fg) midgut (mg) and 
hindgut (hg) progenitor domains. Morphogenesis forms foregut and hindgut pockets as the 
endodermal cup is transformed into a gut tube. By e8.5 hepatic fate specified in a portion of 
the ventral foregut endoderm adjacent to the heart. As the embryo grows the endoderm 
forms a gut tube and the liver domain moves to the midgut. The liver diverticulum (ld) 
forms by e9 and expands into an obvious liver bud (lb) by e10. The liver grows, and by e15 
hepatoblasts are differentiating into hepatocyte and biliary cells. Final maturation of the 
liver is gradual and continues into the postnatal period. 
(Figure taken from[74], figures 1 and 2) 
In the second phase, we see the differentiation from definitive to hepatic endoderm. The 
onset of liver development is characterized by the commitment of midgut endoderm to 
become liver through interactions with cardiac mesoderm which secrete fibroblast growth 
factors (FGFs) [27]. FGFs signaling in the foregut endoderm activated the MAPK pathway is 
necessary for initiation and stabilization of hepatic differentiation [28]. Bone morphogenetic 
proteins (BMPs) (BMP2, BMP4, BMP5, and BMP7) signaling from the septum transversum 
mesenchyme also contributes to hepatic gene induction in the endoderm [29-32]. Wnt 
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signaling along this stage is suppressed but is required in the following stage where the 
hepatic endoderm outgrows into the liver bud[23]. In addition, HNF3 and activin A 
signaling are involved in the process of the specification from endodermal stem cells toward 
the hepatic epithelial lineages as indicated in Figures 2 and 3 [31, 32]. Under the influence of 
these signals, endodermal cells (the liver bud) migrate from the ventral foregut into the 
extracellular matrix (ECM) rich septum traversum, forming the primordial hepatoblasts. 
This migration is accompanied by major remodeling of the extracellular matrix surrounding 
the hepatic cells. Some investigators have tried to induce this process in vitro by 
differentiating ES and iPS cells using various types and configurations of ECM [33]. 
 
 
Fig. 3. Schematic presentation of fetal liver development. The establishment of a fully 
functional liver architecture is not accomplished before postnatal stages and follows upon a 
sequential array of tightly regulated intra- and extracellular signaling pathways, including 
liver-enriched transcription factors (LETFs) and growth factors, cytokines, glucocorticoids 
and hormones, respectively. To distinguish the level of expression and/or regulating role 
among diverse LETFs, different letter sizes are used. Abbreviations: ALB, albumin; AFP, 
alpha-fetoprotein, BMP, bone morphogenic proteins; C/EBP, CCAAT enhancer binding 
protein; CK, cytokeratin; CM, cardiogenic mesoderm; E, embryonic day in rodent liver 
development; FGF, fibroblast growth factors; GGT, c-glutamyltransferase; HGF, hepatocyte 
growth factor; HNF, hepatocyte nuclear factor; OC-2, Onecut transcription factor; ST, 
septum transversum; TGF, transforming growth factor. (Figure taken from[31], figure 2) 
In the third phase, the liver primordium is induced to invade the septum transversum, 
giving rise to fetal hepatocytes (primordial hepatoblasts) which are bi-potent and may 
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proliferate of later differentiate into hepatocytes and cholangiocytes (biliary cells). Markers 
of hepatoblasts inherent in this phase are GATA4, HNF4alpha, HNF6, hepatic alpha-
fetoprotein [AFP], albumin [ALB], and biliary cytokeratin (CK 17/CK19) [29, 30, 32].  
Hematopoietic stem cells (HSCs) colonize the liver bud, thereby emitting a growth signal for 
the liver. Hematopoietic tissue and hepatoplasts subsequently release additional growth 
factors to further develop both tissues. Hepatoblasts continue to proliferate and start 
expressing placental alkaline phosphatase, intermediate filament proteins (cytokeratins 
CK14, CK8, and CK18), c-glutamyltransferase, and later also alpha1-antitrypsin, glutathione 
S-transferase P, C/EBP, lactate dehydrogenase, and muscle pyruvate kinase [29-32].  
At this stage three cell populations exist: (a) hepatocyte-committed cells that exclusively 
express hepatocyte markers, such as AFP and ALB, (b) cholangiocyte-committed progenitor 
cells, expressing biliary cell markers such as CK19, and (c) a bipotential hepatoblast 
population, expressing both hepatic and biliary markers. Bipotential hepatoblasts then 
proceed through a series of maturation steps which entail proliferation, cellular growth, and 
functional maturation. These final in vivo steps are induced by various extracellular signals 
such as: (1) dexamethasone, which induces albumin production and downregulates alpha-
fetal protein production; (2) transforming growth factor beta, which inhibits hepatocyte 
proliferation and increases albumin production; (3) oncostatin M, mostly produced by 
HSCs, which induces tight cell-cell contacts, necessary for maximum differentiated 
hepatocyte function, maintenance of albumin production, and upregulation of other various 
hepatocyte functions; (4) HGF, excreted by mesenchymal cells or nonparenchymal liver 
cells, antagonizes the latter process, resulting in support of growth and differentiation of the 
fetal hepatocytes. The hormone insulin synergistically promotes this effect [27, 29, 31].  
In parallel, the percentage of bipotent cells is markedly reduced. At this point, although cells 
continue to proliferate, most of them are unipotent and irreversibly committed to either the 
hepatic or cholangic lineage [29-32]. Complete functional hepatic maturation ultimately 
takes place after birth upon coassistance of HGF, produced by the surrounding 
nonparenchymal liver cells (sinusoidal, stellate, and endothelial cells) [27, 31]. About half of 
the active genes tested in the liver are bound by the transcription factor HNF4 alpha and it is 
suggested that it directly regulates hepatic genes and is an important transcription factor 
during the differentiation process of ES and iPS cells into mature hepatocytes [34, 35].  
It is important to mention that mouse iPS cells exhibit full potential for fetal liver 
development in embryos derived solely from mouse iPS cells by tetraploid 
complementation compared to wild-type embryos as indicated by similar levels of 
hepatocyte marker mRNA and liver specific cell type protein expression levels. In addition, 
liver Hematoxylin and Eosin (H&E) stained sections presented a similarity in liver 
morphology between the two [36].  
2.1.2 Induction of ES and iPS cell differentiation into hepatocyte-like cells in vitro 
The resultant paradigms, taking these cues into account, can thus be broadly grouped in 
terms of temporal regulation through cytokine addition or spatial regulation using various 
extracellular matrix configurations. Various configurations for generating hepatocyte-like 
cells in vitro involve culturing human ES and iPS cells on extra cellular matrix and inducing 
differentiation with hepatocyte development stage specific factors in order to maximize the 
yield of cells at each stage which will determine the overall differentiation yield of the 
process.  
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As mentioned above, the first step involves the differentiation of pluripotent human ES into 
endodermal cells and most differentiation paradigms utilize Activin A which mimics Nodal 
signaling. At the end of this stage, most of the cells lost the expression of the pluripotent 
marker Oct4 while concomitantly gaining strong expression of definitive endoderm (DE) 
transcription factors Sox17, FoxA2 as well as GATA4 [36-38]. The later steps of 
differentiation induce endodermal like cells to differentiate into mature and fully functional 
hepatocytes while utilizing different ECMs and various factors for about 15 additional days 
[36-38]. 
The human ES cells exhibited a similar differentiation efficiency as human iPS cells while 
using the same differentiation procedure (about 81% albumin positive cells) as well as 
similar hepatocyte mRNA fingerprints [36] . In addition, cell properties of primary human 
hepatocytes such as albumin and urea secretion, as well as cytochrome CYP450 activity 
were similar in vitro between hepatocyte-like cells generated from human ES as well as 
those generated from human iPS cells, although lower compared to primary isolated 
hepatocytes (10 fold difference for urea and albumin secretion and 30 fold difference for 
CYP450 isozyme activities after phenobarbital induction) [38]. While comparing the 
expression of a series of genes encoding phase I and phase II hepatic enzymes between 
cadaveric liver samples and hepatocyte-like cells, it was indicated that the level of mRNA 
was similar between the ES and iPS derived hepatocyte-like cells while lower compared 
with adult liver samples in most cases [36]. This may indicate that differentiated cells are not 
mature enough and this step of the differentiation procedure demands further optimization 
[36, 38].  
Human ES and iPS cell derived hepatocytes were shown to contribute to the liver 
parenchyma in vivo and were stained positive for albumin 7 days after their injection to the 
right lateral liver lobe of newborn mice, which exemplifies the potential of human iPS cells 
in regenerative medicine therapeutics [36]. 
2.2 Differentiation paradigms utilizing tissue engineering 
A key requirement for effective tissue engineering is the cellular environment that allows 
the cells to maintain the functional capacity observed in the in vivo environment. Often the 
environment mimics some critical aspects of the in vivo setting through proper control of 
the materials and mechanical properties as well as the chemical milieu.  
A consideration with tissue-engineered constructs is the presence of exogenous chemical 
and mechanical stimuli such as soluble growth and differentiation factors as well as 
mechanical forces (e.g., cyclic mechanical loading, fluid shear).  
2.2.1 Matrix configuration 
Culturing cells in various controlled three-dimensional (3D) environments has proven to be 
a successful differentiation technique. This is thought to be a result of mimicking the in vivo 
histoarchitecture of liver, incorporating cell-matrix interactions as well as soluble cues.  
Several ECMs are present in liver development. One study compared the effect of using 
type I collagen, fibronectin, laminin, and MatrigelTM on directing hepatic differentiation. 
Cells were cultured for 7 days in embyoid bodies (EBs) before being transferred to one of the 
substrates. This mimics to some extent the liver development stage where endodermal cells 
migrate into the ECM rich septum transversum. Type I collagen was shown to cause the 
greatest increase in liver specific genes, with MatrigelTM also showing a beneficial effect[39].  
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Therefore, one research group utilized a collagen scaffold as a 3D network for hepatic 
differentiation. Mouse ES cells were cultured in an EB configuration and implanted into a 
collagen scaffold and cultured in media containing aFGF, HGF, oncostatin M, 
dexamethasone, and insulin transferrin sodium selenite (ITS). Cells cultured in the 3D 
configuration showed gene expression of AFP, ALB, glucose 6-phosphate (G6P) and 
tyrosine aminotransferase (TAT) after 6 days in cultures as opposed to 12 days in an EB 
configuration alone. However, these cells stained positive for albumin protein, but not for 
the CK-18 protein. Following implantation into the median lobe of the liver of a nude mouse 
for 14 days, the cells stained positive for both CK-18 and albumin proteins. This result 
signifies that cells were not completely matured by the in vitro protocol [40]. While this 
study showed the advantages of 3D culture, most studies fail to demonstrate a genetic or 
functional advantage relative to standard monolayer differentiation protocols. Other groups 
have used 3D cultures to provide a configuration suitable for direct implantation, 
eliminating the need to remove cells from culture by using biodegradable and/or 
biocompatible materials. For example, one group used a polyurethane foam spheroid 
culture to direct differentiation of mouse ES cells. Embryoid bodies were inoculated into a 
block of polyurethane foam (PUF) to induce the formation of spheroids in the pores of the 
scaffold. Induction of hepatic differentiation was accomplished by supplementing the media 
with aFGF, HGF, oncostatin D, dexamethasone, and ITS. Analysis of gene expression 
showed the expression of endoderm markers transthyretin (TTR) and AFP as well as 
hepatocyte specific albumin, arginase, and tryptophan 2,3-dioxygenase (TDO) expression. 
Notably, ES cell derived hepatocyte like cells demonstrated ammonia clearance and albumin 
secretion rates within the range, albeit on the low end, of those seen for primary rat 
hepatocytes seeded in the PUF scaffold.   However, this method of differentiation is lengthy 
and immature endoderm markers were still present at the end of the 30 day protocol[41]. 
Biodegradable polymer scaffolds have also shown to be an effective three-dimensional 
environment for hepatic differentiation. One study allowed ES cells to form EBs for 5 days 
before being mixed them with Matrigel™. The cell suspension was then seeded into a rigid 
polymer network comprised of poly-L-lactic acid (PLLA) and polyglycolic acid (PGA). The 
cells formed spheroids along the polymer fibers and were cultured for 20 days with 
dexamethasone, dimethyl sulfoxide (DMSO), FGF4, HGF, oncostatin M, and ITS. After the 
culture period, the cells showed expression of AFP, ALB, G6P, TTR, and CK-18 and the 
ability to secrete albumin, uptake low-density lipoprotein (LDL) and store glycogen [42].  
Encapsulation of ES cells in alginate has been explored as a method for the control of hepatic 
differentiation. The capsules allow the diffusion of nutrient, oxygen, and growth factors into 
the capsules while sequestering the cells.  This technique has been widely used in the past to 
induce stem cell differentiation and maintain hepatocyte function, making it an ideal 
candidate for controlled hepatic differentiation. For instance, one group encapsulated 5-day-
old embryoid bodies derived from mouse ES cells in a 2% alginate solution. The media was 
supplemented with aFGF, HGF, oncostatin M, dexamethasone, and ITS, similar to those 
factors previously used by other research groups. RT-PCR analysis determined that this 
methods results in the expression of endoderm (AFP) and hepato-specific (ALB, Cyp7A1, 
TAT, TTR, and CK18) genes.  The cells produced albumin and urea, but only with growth 
factor supplementation. If one takes a closer look at the temporal addition of growth factors 
in these systems, several similarities exist. FGF is usually added at early time points in order 
to promote differentiation of definitive endodermal cells into hepatic endoderm cells. This is 
almost always followed by HGF supplementation, mimicking signaling from the 
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mesenchyme which promotes growth and differentiation of fetal hepatocytes. Lastly, 
oncostatin M, dexamethasone, and ITS are added, as these factors are known to promote 
hepatocyte maturation. Sequential supplementation therefore mimics in vivo development. 
In addition, ES cells are allowed to form embryoid bodies prior to being cultured in a 3D 
environment. This allows the formation cell-cell interactions known to increase hepatocyte 
function during development.  Although these aforementioned methods yield hepatocyte-
like cells from a functional perspective, growth factors are expensive and therefore these 
approaches are not amendable to scale up for clinical application.  
A different approach is the use of cellular encapsulation to control lineage commitment and 
final maturation of murine ES cells. The novelty of this method lies in the fact that no 
growth factor supplementation is required to direct hepatic differentiation. This was 
accomplished through the manipulation cell seeding density and alginate concentration. 
These two variables dictate the size of cellular aggregates that form within the capsule 
which in turn direct differentiation. It was found that a 2.0% w/v alginate concentration and 
a 5x106 cells/mL seeding density were the optimal parameters for hepatic differentiation 
[43, 44]. Genetic analysis showed the expression of a variety of Cyp450s as well as CK-18. In 
addition, albumin and urea secretion as well as glycogen storage were shown and reached a 
maximum around day 20 in culture. This method demonstrates a way to obtain a high yield 
of hepatocyte-like cells through inducing cell-cell interactions known to upregulate 
hepatocyte function during development, thus eliminating the need for growth factor 
supplementation. In addition, the cells can be recovered from the capsule through 
depolymerization without effecting cell viability.  Scalability is also significant, as 
generating large numbers of cells would simply involve producing large batches of 
capsules. With all these advantages taken into consideration, this technique is amenable to 
the mass production of hepatocyte like cells and thus has the potential for clinical utility. 
2.2.2 Coculture 
A co-culture of ES cells with another cell type present during hepatic development or in the 
adult liver cell has been shown to induce hepatic differentiation. The supporting cell type 
directs the ES cells towards the hepatic lineage by introducing cues resulting from soluble 
factors, cell-cell interactions, or a combination of the two. Thus, this approach is performed 
by separating the cells with a porous membrane or with the cells in direct contact with one 
another. Both methods have been shown to induce hepatic differentiation of embryonic 
stem cells with careful choice of feeder layers. In fact, investigators often develop their own 
cell lines optimized to drive hepatic differentiation. For example, one group first developed 
a protocol to differentiate endoderm cells by culturing the cells on Matrigel™ and 
supplementing the media with activin A and HGF [45]. The endoderm cells were separated 
by fluorescence-activated cell sorting (FACS), made possible by the transfection of enhanced 
GFP (EGFP) under the control of an AFP promoter. The purified cells were then further 
exposed to a co-culture with MLSgt20 cells, a cell line cloned from fetal murine stromal cells 
experimentally shown to promote hepatic differentiation in ES cells [46].  Combining the 
results of the two studies, the AFP positive endoderm cells were contact co-cultured with 
the MLSgt20 cells. The co-cultured cells expressed markers for both immature (GATA4, 
AFP) and mature (Alb, TAT, TO, CYP3a4/7) hepatocytes at the end of the culture period. 
The cells also showed the ability to clear ammonia and store glycogen. However, gene 
expression was not identical to that of adult human liver hepatocytes [47]. A drawback of 
contact co-culture is that the hepatocyte like cells must be separated from the supporting cell 
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type after the culture period. To eliminate the need for purification of differentiated cells, 
one group co-cultured three human liver non-parenchymal cell lines with ES cells using a 
transwell membrane. Mouse ES cells containing a GFP gene with and albumin promoter 
were cultured in suspension for 2 days to facilitate embryoid body formation.   The EBs 
were then cultured on a poly-amino-urethane (PAU) coated non-woven 
polytetrafluoroethylene (PTFE) fabric that allowed the cells to adhere. The media was 
supplemented with basic FGF and activin A for 3 days. The ES cells were then co-cultured in 
Matrigel layered transwells with the human cells lines growth-arrested with mitomycin C. 
Cholangiocytes, liver endothelial, and hepatic stellate cell lines were chosen due to their 
secretion of soluble factors that have shown to be important for liver regeneration. 
Cholangiocytes generate IL-6 and TNF-, liver endothelial cells produce FGF4 and vascular 
endothelial growth factor (VEGF) and hepatic stellate cells produce HGF. The cells were co-
cultured with media supplementation of dHGF and DMSO for 8 days and dexamethasone 
for the final 3 days of culture. The differentiated GFP positive cells were separated by cell 
sorting and showed a yield of 70%. These cells expressed both hepatocyte markers as well as 
endoderm markers, demonstrating that the cells were not fully mature. They also stained 
positive for albumin and GFP, secreted albumin, and metabolized ammonia, lidocaine, and 
diazepam. However, albumin secretion and metabolic activity occurred at lower levels than 
primary mouse hepatocytes[48]. Another example of a non-contact co-culture was 
demonstrated using cynomolgus monkey ES cells with mouse fetal liver-derived cells to 
simulate the environment of the developing liver. The ES cells lost pluripotent markers and 
expressed AFP, ALB, CYP7A1, and HNF4, an important transcription factor for mature 
hepatocytes. The cells also stained positively for AFP, albumin, alpha1AT, and HNF4, as 
well as for Hep Par 1, an anti-hepatocyte antibody. Functional analysis also showed 
glycogen storage through Periodic acid-Schiff (PAS) staining as well as ammonia 
clearance[49]. 
While the aforementioned co-culture systems utilize non-parenchymal cells or fetal liver 
cells as a support cell type, the use of hepatocytes as the feeder cell type in co-culture 
differentiation schemes has also been attempted. Moore et al. examined the effects of co-
cultivated hepatocytes on the hepatospecific differentiation of murine ES cells[50]. 
Hepatocytes co-cultured with cadherin-expressing ES cells markedly enhanced ES cell 
differentiation toward the hepatic lineage, as demonstrated by hepatic-like cuboidal 
morphology, heightened gene expression of the late maturation marker G6P in relation to 
the early marker AFP, and the intracellular localization of albumin. The effect was mediated 
by cadherin, since it was reversed through E-cadherin blockage and inhibited in control ES 
cells with reduced cadherin expression. Direct contact co-cultures of hepatocytes and ES 
cells maximally promoted ES cell commitment towards hepato-differentiation. This study 
showed that both soluble signaling and cell-cell interaction creates a synergistic effect that 
drives hepatic differentiation.  
Cho et al. developed another co-culture method with hepatocytes[51]. A collagen gel was 
formed on tissue culture dishes and primary rat hepatocytes were plated after gelation. A 
thick collagen layer was then deposited on top of the hepatocytes. We have previously 
shown that this collagen sandwich hepatocyte culture maintains hepatocyte function in 
vitro. Murine ES cells were then seeded on the thick collagen layer and cultured in this 
configuration for 10 days. At this stage, the ES cells were removed from the collagen layer 
by dispase treatment while leaving the collagen sandwiched hepatocytes intact. RT-PCR 
demonstrated the presence of endoderm markers Foxa2, Sox17, and AFP and the absence of 
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mesoderm and ectoderm markers. The presence of Foxa2 and AFP were confirmed by 
immunostaining, and flow cytometry showed that they were expressed in 95% of cells. In 
addition, the cells proliferated and stopped expressing Oct4, a marker for pluripotency. 
These results showed that mouse ES cells cultured on top of collagen-sandwiched 
hepatocytes differentiated and proliferated into a uniform and homogeneous cell population 
of endoderm-like cells. However, the endoderm cells did not express albumin, signifying 
that they had not yet committed to the hepatic lineage. To further mature the cells, they 
were co-cultured for 20 days with fibroblasts due to the in vivo interactions of the endoderm 
with the mesenchyme during development. The media was supplemented with oncostatin 
M, ITS, and dexamethasone. The resulting hepatocyte like cells expressed hepatospecific 
genes albumin, alpha-1-antitrypsin (AAT), CK-8, CK-18, TTR, and CYP2A13 and displayed 
morphology similar to that of primary rat hepatocytes. Immunostaining demonstrated the 
presence of albumin and CK-18 while functional analysis showed the cells could synthesize 
urea. This study showed the generation of a homogeneous population of hepatocyte-like 
cells from ES cells[51]. However, the drawback of this method is that two separate co-
cultures are required to direct differentiation, with one feeder cell being the scarce cell type 
that we are trying to generate. 
2.2.3 Metabolic engineering 
A distinguishing feature of adult hepatocytes is the high content of mitochondria and high 
level of oxidative metabolism. On the contrary, ES cells contain a much smaller amount of 
mitochondria and produce energy mainly through the glycolytic pathway. Recent studies 
show that metabolic additives that promote carbon backbone oxidation can be used to help 
direct differentiation towards the hepatocyte lineage. One such method utilizes sodium 
butyrate treatment to generate an enriched population of hepatocyte-like cells from 
embryonic stem cell [52]. ES cells were plated on gelatin and the media was supplemented 
with DMSO for the first 5 days of culture. Sodium butyrate replaced DMSO for the next 6 
days, and cells were replated onto collagen coated or non-coated polystyrene at various time 
points in order to perform metabolic analysis. Significantly higher levels of urea secretion 
and albumin positive cells were observed in a 2.5 mM sodium butyrate condition on both 
substrates. It was also shown that mitochondrial mass increased from days 5-8 in culture, 
which is characteristic of hepatic differentiation. However, the percentage of albumin 
positive and high mitochondrial activity cells was still less than mouse hepatoma cells. 
These results imply that these cells represent an immature hepatocyte phenotype. A 
subsequent study was conducted in order to further differentiate the cells into  
mature hepatocyte-like cells [53]. The immature cells were treated with S-
NitrosoAcetylPenicillamine (SNAP), a nitric oxide donor. Nitric oxide is known to induce 
the synthesis of mitochondria, thus possibly facilitating a further increase of mitochondrial 
mass to levels seen in mature liver cells. After the 11 days of culture conditions that were 
found to induce partial differentiation using sodium butyrate, cells were replated on day 12 
and supplemented with various dilutions of SNAP in DMSO for the next 3 days. A 500 μM 
concentration of SNAP significantly increased glucose consumption, lactate production, and 
the percentage of albumin positive cells. From a functional perspective, SNAP treatment 
also increased urea and albumin secretion as well as cytochrome P4507a1 activity relative to 
the other culture conditions. These studies demonstrate that simply altering the ES cell’s 
metabolic activity to more closely resemble those of mature hepatocytes is an alternative 
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strategy to developing hepatocyte-like cells. This novel method circumvents the need for 
media supplementation with expensive cocktails of growth factors or co-culture with 
another cell type. 
3. Utilizing hepatocyte-like cells 
Techniques aimed at obtaining a homogeneous population of hepatocyte-like cells with 
functional characteristics similar to native hepatocytes from ES cells are rapidly improving. 
As these methods progress, applications taking advantage of a constant supply of 
hepatocytes are being developed in parallel. One application is the use of hepatocytes for 
the treatment of liver failure. With the gap between those on the waiting list for a liver 
transplant and the organs available for transplantation growing every year, a renewable 
source of hepatocyte-like cells could potentially alleviate this problem. Bioartificial livers 
containing functional hepatocyte-like cells could be used to keep patients alive while 
waiting for a transplant. In addition, decellularizing livers unsuitable for transplant and 
reseeding them with functional cells could increase the donor pool. In conjunction, these 
two cutting-edge methods could reduce the number of patients who die on the waiting list. 
Finally, the important role the liver plays in the metabolic clearance of drugs makes 
hepatocytes an important research tool for the pharmaceutical industry. By including 
microfluidic technology, the number heaptocytes needed per assay can be greatly reduced, 
facilitating high-throughput screening of new chemical entities. This next section will 
discuss the current state of these applications of hepatocyte-like cells derived from ES cells. 
3.1 Decellularized liver scaffolds for implantation 
Using hepatocyte-like cells for transplantation is a potentially very exciting application. As 
mentioned earlier, a large gap exists between the number of patients waiting for a liver 
transplant and the number of available liver grafts. With this gap growing each year, an 
alternative source of transplantable livers is greatly needed. Although the differentiation of 
hepatocyte-like cells from embryonic stem cells has been accomplished through a variety of 
methods, creating a three-dimensional organ structure is challenging due to the nutrient and 
oxygen limitations that occur in the engineered tissue. The liver consists of a complex 
network of extracellular matrix proteins as well as microvasculature critical to organ 
function. One approach to provide the complex 3D environment of the liver is not to try to 
recreate it from scratch, but rather to use natural decellularized liver scaffolds. Data show 
that the native 3D matrix can promote cell engraftment, survival, and sustained hepatic 
function over time. In addition, by preserving the native microvasculature structure, the risk 
of ischemic damage or lack of perfusion is minimized. This approach has the potential of 
utilizing livers unsuitable for transplantation as a source of scaffolds to seed hepatocyte-like 
cells derived from ES cells, thereby increasing the number of livers available for 
transplantation. 
Using the liver as a scaffold requires that the organ be decellularized while leaving the 3D 
architecture intact. Following decellularization, the scaffold must be reseeded with the 
proper cell types engrafting to their appropriate locations within the tissue to promote 
function. This has been accomplished by perfusing sodium dodecyl sulfate (SDS) solutions 
through the portal vein of a rat liver for 72 hours [54]. The result was a translucent structure 
free of cells which preserved the 3D architecture of the liver, Figure 4a. Most notably, the 
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microvascular tree was preserved, as shown in Figure 4b. Using the scaffold, cells were 
seeded by injecting 12.5 million cells in 4 doses at 10-minute intervals. This approach 
resulted in a grafting efficiency greater than 90%, and perfusion of the recellularized 
scaffold showed 80% viability over 2 days. Since a liver consists of non-parenchymal cells as 
well as hepatocytes, epithelial cells were also seeded and engrafted in the lining of the 
vessel. Moreover, epithelial cell seeding did not affect hepatocyte viability, providing proof 
of concept that other cell types could also be successfully seeded. The scalability of the 
system was also tested, injecting a total of 200 million cells using the 4-dose approach. This 
cell total represents 20% of the adult rat liver mass, double the amount required to provide 
therapeutic benefit. 
 
 
Fig. 4a. Rat liver during the decellularization process. SDS was perfused through the portal 
vein, leaving a translucent, cell free structure which maintained native liver architecture. 
From left to right, the images show the liver at 0, 18, 48, 52, and 72 hours of the SDS 
perfusion, respectively. (Figure taken from [54], Figure 1) 
 
Fig. 4b. Portal (red) and venous (blue) corrosion cast of normal (left) and decellularized liver 
(right). Comparison of the two shows that the decellularization process preserves the native 
liver microvasculature. (Figure taken from [54], Figure 2) 
Analysis of the reseeded hepatocytes showed gene expression similar to that of long-term 
stable cultures (e.g. collagen sandwich) of hepatocytes. Immunohistochemical analysis of 
UGT1a, G6pc, and albumin showed staining at levels comparable to adult livers. Functional 
analysis showed urea synthesis significantly higher that hepatocyte sandwich and similar 
albumin secretion rates. However, albumin production was much lower than that of adult 
rat livers. The recellularized liver was then transplanted into a rat for 8 hours to investigate 
the effect of shear stress due to blood flow. Transplantation did not affect hepatic function, 
viability, or morphology in any significant way. Other investigators successfully 
decellularized a liver and seeded the matrix with both hepatocytes and other epithelial cells 
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[55]. These studies demonstrate the feasibility of using a decellularized liver matrix as a 
scaffold for hepatocytes. The inclusion of other non-parenchymal cells and evaluation of the 
transplant after long periods in vivo still needs to be performed prior to bringing this 
approach to the bedside. This may further require the development of techniques to derive 
hepatic nonparenchymal cells from ES cells. 
3.2 Bioartificial liver devices 
The shortage of donor livers has also prompted researchers to develop bioartificial liver 
(BAL) devices, Figure 5. These devices aim to provide temporary assistance to patients with 
liver failure while waiting for a donor organ. Early BAL concepts were modified dialysis 
systems which did not incorporate living cells, [56] and were found to be limited in efficacy. 
Since the liver provides a host of biochemical processing and detoxification functions that 
are essential to life, it was thought that an effective device should contain liver parenchymal 
cells (e.g. hepatocytes). Cells were added to the dialysis systems, and again poor results 
were obtained, in this case because the bioreactor design itself did not allow for sufficient 
metabolite transport (especially oxygen), and as a result the cells did not function properly 
or even survive. Next, a support structure was built that allows for the convective and 
diffusive transport of plasma metabolites to and from the cells in the device [57]. Many 
creative operational strategies and designs exist [58]; [59]; [60], ranging from packed bed 
bioreactors [61, 62], to flat plate bioreactors [63]. It was found that hepatocytes can only   
 
 
 
 
Fig. 5. Schematic of a radial flow Bioartifical Liver Device. Red arrows show the direction 
of medium flow and in blue is the location of the seeded hepatocytes. The design includes 
patterned microgrooves to decrease shear stress on the seeded hepatocytes. (Figure taken 
from [67], Figure 1) 
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withstand low levels of fluid shear stress, therefore in a recent modification of the flat plate 
geometry, cells were seeded at the bottom of grooves to allow for higher flow rates, thus 
increasing mass transport within the device, while keeping shear stress at the cell surface to 
a low level [64, 65]. 
The high metabolic activity of hepatocytes makes the transport of oxygen a significant 
technical concern in BAL devices. In fact, transport limitations have led to the loss of hepatic 
function over time and the failure of many BAL devices based on hollow fiber technology 
that have undergone clinical trials. To alleviate this issue, semi-permeable membranes have 
been introduced into devices to increase the oxygen tension within the device. However, a 
device would require a surface area of approximately 10 m2 to provide therapeutic benefit 
[66]. Therefore, the incorporation of an internal membrane oxygenator would create scale up 
issues. To address these problems, a radial stacked plate bioreactor was developed to 
increase the surface area to volume ratio of the device. The design was devoid of a semi-
permeable membrane and therefore required perfusion at high volumetric flow rates in 
order to create the necessary oxygen tension to maintain hepatocyte function. Nevertheless, 
hepatocytes will also lose function above a critical shear stress. Therefore, 
photolithographically patterned microgrooves were incorporated to shield the cells from the 
resulting high shear rates required for sufficient convective oxygen transport. 
The requirement of high-flow rates and low shear stress is a non-trivial engineering 
problem. In order to examine the effect of microgrooves, computation fluid dynamics 
(CFD) was employed to characterize the device. CFD analysis showed that varying width 
of the microgrooves with the distance from the center of the bioreactor results shear 
stresses well below detrimental levels throughout the device. Incorporating an oxygenator 
within the perfusion circuit, design and operating parameters were optimized that 
provided sufficient convective oxygen delivery and acceptable shear stresses. These 
critical parameters resulted in 95% viability of hepatocytes under perfusion after 36 hours 
within the device. In addition, urea and albumin secretion levels were significantly higher 
than a flat plate bioreactor and comparable to hepatocytes co-cultures with fibroblasts. 
The device produced 2,100 μg of albumin per day, as compared to 19x105 μg/day 
required for a therapeutic effect. To be clinical useful, this device would need to be scaled 
by a factor of 905, which would allow the device to be operated without exceeding the 
recommended clinical priming volume[67]. 
As opposed to ex vivo bioartificial liver devices, an implantable liver assist device (LAD) has 
been developed by engineering a hepatic organoid.  The implantable construct comprised of 
a PAU-coated PTFE non-woven fabric covered with a polyethylene-vinyl alcohol membrane 
layered with a polyester supporting fabric. Based on the method described in Section 2.2.2, 
human cholangiocytes, liver endothelial cells, and hepatic stellate cells were injected into an 
LAD coated with FGF-2 to facilitate angiogenesis. The LAD performance was evaluated 
through implantation into mice after a 50% hepatectomy for 7 days. While LAD with only 
hepatocytes did not survive, devices with non-parenchymal cells exhibited the formation of 
organotypic structures in the LAD similar to the liver acinus. Additionally, in vitro analysis 
showed that the organoid significantly improved ammonia and lidociane clearance as well 
as albumin secretion relative to device with seeded with hepatocytes alone. This study 
showed that the inclusion of non-parenchymal cells in liver assist devices has the potential 
of improving in vivo performance. 
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3.3 In vitro drug screening systems 
According to the Pharmaceutical Research and Manufacturers of America (PhRMA) U.S. 
drug companies spent $62.4 billion on research and development in 2009. Studies indicate 
that it can cost more than $800 million, of which 80% is spent on clinical trials and 
development, and will take between 8 and 10 years of development to bring a new drug to 
market. Among candidate drugs that make it past Phase I clinical trials, 50% fail due to 
human toxicity and bioavailability issues. Moreover, of all candidate drugs, 90% do not 
make it through final stages of development. This tremendous attrition rate has not 
improved in recent years. To curb such costly failures, a significant amount of research has 
been dedicated to identifying in vitro screening systems; i.e., approaches that can be utilized 
in preclinical phases of discovery and development that offer greater utility in predicting in 
vivo subcellular and cellular physiological responses. 
Currently, a majority of hepatic in vitro screening assays employed within the field of drug 
metabolism and pharmacokinetics (DPMK) utilize hepatocytes cultured under fully static 
conditions. In such assays, hepatocytes are either adhered to the bottom of a microtiter well-
plate to which culture medium containing candidate drug(s) is subsequently added; or else 
the hepatocytes are maintained inside the microtiter well in suspension in the media. The 
microtiter plate is shaken to facilitate mixing and transport, but there is no means for 
providing a continuous flow of culture media over the cells. 
The lack of continuous flow produces functional limitations in these conventional static 
systems when compared to microfluidic systems. The presence of flow helps regulate the 
concentrations of both metabolites and cellular by-products in the immediate vicinity of the 
hepatocytes; whereas in a static system these concentrations are ever-changing until a 
saturation/depletion condition is attained through accumulation, uptake, and reaction. In a 
flow system it is possible to maintain a pseudo steady state (equilibrium) which results in 
optimal working characteristics. Furthermore, in a static well the system is usually mass 
transport limited; flow can remedy this by the addition of convective mode of mass 
transport.  
A variety of devices have been developed for this purpose [68-70], and in particular to 
determine parameters for multi-compartmental physiologically-based pharmacokinetic 
(PBPK) models, Figure 6. For example, a multi-tissue compartmental device has been 
developed that incorporates a large liver compartment for the assessment of drug 
absorption both in the liver as well as in other metabolizing tissue types [71-73]. More 
specifically, the Hμrel® Corporation has developed a liver-specific microfluidic chip that 
focuses on liver metabolism, with the possible application to liver toxicity assessment, 
Figure 7. The Hμrel®  device allows for the seeding of various cell types to emulate the in 
vivo components affecting pharmacokinetics. The device consists of separate chambers, each 
seeded with a specific cell type. Device testing demonstrated that the flow co-culture format 
in the device resulted in better predictions of in vivo clearance rates compared to static 
cultures and flow-based monoculture models, across a wide range of cytochrome P450s. The 
reason for increased hepatocyte function when flow is incorporated is not yet known for 
certain. One possibility is that increased mass transport in the system leads to a thinner 
boundary layer in addition to faster removal of unwanted by-products, together resulting in 
an observed increased clearance. Regardless of the mechanism, the Hμrel®  device yields an 
in vitro analogue to PBPK models utilizing minimal amounts of cells and drug, thus 
facilitating high-throughput screening of new chemical entities.  
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Fig. 6. Example of multi-compartmental MEMs model utilized to determine PBPK values 
for use in in silico simulations. The new chemical entity is dosed on one side of the Caco-2 
cells, where it must be absorbed prior to reaching the microchannels. The absorbed drug 
then passes into the liver for metabolic clearance prior to being re-circulated and reaching 
the target tissue.  
 
Fig. 7. Geometry of the static and flow configurations in the HREL® system. The assembly 
of a HµREL® housing set with four biochips. The components of the chip housing and 
interface are, from the top – adapter, housing top, HµREL® biochips, housing bottom. The 
complete setup of the HµREL® prototype instrument then involves connecting inlet and outlet 
tubing to the adapter. The inlet tubing is then fed through a peristaltic pump, and connected to 
a reservoir that contains the media with the test compound of interest. The outlet tubing is also 
inserted into the reservoir to complete the recirculation loop. (Figure taken from [75], Figure 1) 
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4. Future directions 
Considerable progress has been made in differentiating ESCs into liver cells; however, 
current protocols have not yet produced cells that express a completely adult-like mature 
hepatocyte. In fact, criteria that define what is an acceptable functional human stem cell-
derived hepatocyte will need to be established and standardized. ESC differentiation 
protocols typically do not yield a pure hepatocyte population, and often times sorting 
protocols are needed. Methods to scale-up such protocols to the therapeutic scale of a 
human patient will need to be developed. There remains safety concerns (e.g. 
tumoregenicity) when using ESCs and iPSC for cell transplantation which cannot easily 
investigated in rodent models and will require further analysis in more “human-like” 
systems, such as nonhuman primates. On a short-term basis, human hepatocytes derived 
from ESCs or iPSCs may be effectively used for toxicology studies on xenobiotics as well as 
drug safety screening. The development of devices that contain such cells for high 
throughput testing is an important avenue for the future in this area, and special 
consideration should be taken to make such systems easy to use at the point of care or in the 
field. The ability to derive cells that are patient-specific provides a unique opportunity to 
better understand patient variability in their sensitivity to drugs as well as potentially 
develop individualized patient-specific drug regimens. 
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